Manhattan Scientifics, Inc. Stock

Equities

MHTX

US5631221000

Entertainment Production

Market Closed - OTC Markets 01:35:17 2024-04-26 pm EDT 5-day change 1st Jan Change
0.00165 USD +37.50% Intraday chart for Manhattan Scientifics, Inc. 0.00% -34.62%
Sales 2022 0.05 Sales 2023 - Capitalization 1.45M
Net income 2022 -2M Net income 2023 -1M EV / Sales 2022 88,184,960 x
Net cash position 2022 65K Net cash position 2023 7K EV / Sales 2023 -
P/E ratio 2022
-1.64 x
P/E ratio 2023
-1.25 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 84.55%
More Fundamentals * Assessed data
Dynamic Chart
Manhattan Scientifics, Inc Announces Resignation of Frank Georgiou as Member of the Board of Directors CI
Manhattan Scientifics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Manhattan Scientifics, Inc. Auditor Raises 'Going Concern' Doubt CI
Manhattan Scientifics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Manhattan Scientifics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
More news
1 day+37.50%
Current month-45.16%
1 month-55.26%
3 months-32.00%
6 months-56.41%
Current year-34.62%
More quotes
1 week
0.00
Extreme 0.0012
0.00
1 month
0.00
Extreme 0.0012
0.00
Current year
0.00
Extreme 0.0012
0.01
1 year
0.00
Extreme 0.0012
0.01
3 years
0.00
Extreme 0.0012
0.04
5 years
0.00
Extreme 0.0012
0.05
10 years
0.00
Extreme 0.0012
0.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 07-10-31
Founder 87 92-07-30
Members of the board TitleAgeSince
Founder 87 92-07-30
Chief Executive Officer 72 07-10-31
More insiders
Date Price Change Volume
24-04-26 0.00165 +37.50% 106,973
24-04-25 0.0012 -14.29% 200,000
24-04-24 0.0014 0.00% 705,250
24-04-23 0.0014 -17.65% 303,000
24-04-22 0.0017 0.00% 300,000

Delayed Quote OTC Markets, April 26, 2024 at 01:35 pm EDT

More quotes
Manhattan Scientifics, Inc. is focused on technology transfer and commercialization of these transformative technologies. The Company operates as a technology incubator. Its business model is to identify significant technologies; acquire them or the rights to them; secure the services of inventors, engineers or other staff who were instrumental in their creation; provide or contract for suitable work facilities, laboratories, and other aids where appropriate; prototype the technologies to demonstrate proof of principle feasibility; secure patent and or other intellectual property protection; secure early customers for product trials where feasible and appropriate; and commercialize through licenses, sales or cooperative efforts with other manufacturing and distribution firms. Its business model is based on licensing metals technology to metals manufacturers. Its technologies are in a development phase.
More about the company